New York City-based Flatiron Health designs and develops oncology-specific electronic health record software, and aids in curating and developing real-world evidence for cancer research, Roche said.
Under terms of the acquisition, Flatiron Health will continue to operate as a separate legal entity and maintain its independence, as well as its business model, partnerships and existing objectives.
Roche said that the acquisition will allow both it and Flatiron to accelerate their development of data-driven personalized healthcare products in the oncology field, according to a press release.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.